Testosterone
- Generic Name
- Testosterone
- Brand Names
- Androderm, Androgel, Axiron, Fortesta, Natesto, Striant, Testim, Testopel, Vogelxo
- Drug Type
- Small Molecule
- Chemical Formula
- C19H28O2
- CAS Number
- 58-22-0
- Unique Ingredient Identifier
- 3XMK78S47O
- Background
Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism. Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.
Testosterone was isolated from samples and also synthesized in 1935.
- Indication
Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.
- Associated Conditions
- Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism, Idiopathic Hypogonadotropic Hypogonadism, Puberty, Delayed, Inoperable, metastatic Breast cancer
- Associated Therapies
- -
Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 12
- Registration Number
- NCT01697345
- Locations
- 🇺🇸
Nebraska Cancer Specialists/Midwest Cancer Center - Legacy, Omaha, Nebraska, United States
Testosterone and Weight Loss
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Austin Health
- Target Recruit Count
- 100
- Registration Number
- NCT01616732
- Locations
- 🇦🇺
Austin Health, Heidelberg, Victoria, Australia
Testosterone Administration and ACL Reconstruction in Men
- Conditions
- Interventions
- First Posted Date
- 2012-05-10
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 14
- Registration Number
- NCT01595581
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-04-09
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 227
- Registration Number
- NCT01573442
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States
🇺🇸Marshfield Clinic - Weston Center, Weston, Wisconsin, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Interventions
- First Posted Date
- 2012-03-22
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Marianne Andersen
- Target Recruit Count
- 43
- Registration Number
- NCT01560546
- Locations
- 🇩🇰
Department of Endocrinology, Odense University Hospital, Odense, Denmark
The VO2 Increase With Testosterone Addition - Heart Failure (VITA-HF) Trial
- First Posted Date
- 2011-11-10
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 318
- Registration Number
- NCT01469988
- Locations
- 🇨🇦
The University of Alberta (Mazankowski Alberta Heart Institute):, Edmonton, Canada
🇨🇦Ajax / Pickering, Ajax, Canada
🇨🇦Foothills Hospital (University of Calgary), Calgary, Canada
Testosterone and Alendronate in Hypogonadal Men
- Conditions
- Interventions
- First Posted Date
- 2011-10-27
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT01460654
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2018-06-13
- Lead Sponsor
- Acerus Pharmaceuticals Corporation
- Target Recruit Count
- 306
- Registration Number
- NCT01446042
- Locations
- 🇺🇸
Coastal Clinical Research, Mobile, Alabama, United States
🇺🇸Diablo Clinical Reseach Inc., Walnut Creek, California, United States
🇺🇸Capital Clinical Reseach Center, Olympia, Washington, United States
Lybrido for Female Sexual Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2011-09-13
- Last Posted Date
- 2013-07-29
- Lead Sponsor
- Emotional Brain NY Inc.
- Target Recruit Count
- 196
- Registration Number
- NCT01432665
- Locations
- 🇺🇸
Compass Research, Orlando, Florida, United States
🇺🇸Miami Research Associates, South Miami, Florida, United States
🇺🇸Michael A. Werner, MD PC, Purchase, New York, United States
Study on the Effects of Exogenous Testosterone on Threat Perception and Behavioral Avoidance
- Conditions
- Interventions
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2012-10-16
- Lead Sponsor
- University of Texas at Austin
- Target Recruit Count
- 120
- Registration Number
- NCT01408498
- Locations
- 🇺🇸
Seay Building, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.